2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Brignole, Michele; Auricchio, Angelo; Barón-Esquivias, Gonzalo; Bordachar, Pierre; Boriani, Giuseppe; Breithardt, Ole A.; Cleland, John G.F.; Deharo, Jean Claude; Delgado, Victoria; Elliott, Perry; Görenek, Bülent; Israel, Carsten W.; Leclercq, Christophe; Linde, Cecilia; Mont, Lluı́s; Padeletti, Luigi; Sutton, Richard; Vardas, Panos; Zamorano, José Luís; Achenbach, Stephan; Baumgartner, Helmut; Bax, Jeroen J.; Bueno, Héctor; Dean, Veronica; Deaton, Christi; Erol, Çetin; Fagard, Robert; Ferrari, Roberto; Hasdai, David; Hoes, Arno W.; Kirchhof, Paulus; Knuuti, Juhani; Kolh, Philippe; Lancellotti, Patrizio; Linhart, Aleš; Nihoyannopoulos, Petros; Piepoli, Massimo F; Ponikowski, Piotr; Sirnes, Per Anton; Tamargo, Juan; Tendera, Michał; Torbicki, Adam; Wijns, William; Windecker, Stephan; Blomström‐Lundqvist, Carina; Badano, Luigi P.; Aliyev, Farid; Bänsch, Dietmar; Bsata, Walid; Buser, Peter; Charron, Philippe; Daubert, Jean Claude; Dobreanu, Dan; Færestrand, Svein; Heuzey, J.-Y. Le; Mavrakis, Hercules E.; McDonagh, Theresa A.; Merino, José Luís; Nawar, Mostapha M.; Nielsen, Jens Cosedis; Pieske, Burkert; Poposka, Lidija; Ruschitzka, Frank; Gelder, Isabelle C. Van; Wilson, Carol M.

doi:10.1093/eurheartj/eht150

Cited by 2,071 publications

(481 citation statements)

References 171 publications

Supporting

Mentioning

447

Contrasting

Unclassified

Order By: Relevance

“…Despite the overall efficacy of CRT in reducing morbidity and mortality endpoints in patients with HF with systolic dysfunction and ventricular dyssynchrony, its effect remains largely heterogeneous, with patients showing a varying degree of clinical benefit 1, 2, 3, 4, 5. In this context, optimization of the device settings is a logical priority of current device‐related research activity.…”

Section: Discussionmentioning

confidence: 99%

“…Cardiac resynchronization therapy (CRT) is recommended by current guidelines for the treatment of patients with symptomatic heart failure (HF), impaired left ventricular (LV) systolic function, and an electrocardiogram (ECG) which displays evidence of electrical dyssynchrony,1, 2 with established effects on morbidity and mortality 3, 4. However, in spite of the overall beneficial effects of CRT, no early clinical improvement is observed in approximately 30% of CRT recipients 3, 5…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing

Filippatos

Birnie

Gold

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

The AdaptResponse trial is designed to test the hypothesis that preferential adaptive left ventricular‐only pacing with the AdaptivCRT® algorithm reduces the incidence of the combined endpoint of all‐cause mortality and intervention for heart failure (HF) decompensation, compared with conventional cardiac resynchronization therapy (CRT), among patients with a CRT indication, left bundle branch block (LBBB) and normal atrioventricular (AV) conduction. The AdaptResponse study is a prospective, randomized, controlled, single‐blinded, multicentre, clinical trial (ClinicalTrials.gov Identifier: NCT02205359), conducted at up to 200 centres worldwide. Following enrolment and baseline assessment, eligible subjects will be implanted with a CRT system containing the AdaptivCRT algorithm, and randomized in a 1:1 fashion to either a treatment (‘AdaptivCRT’) or control (‘Conventional CRT’) group. The study is designed to observe a primary endpoint in 1100 patients (‘event‐driven’) and approximately 3000 patients will be randomized. The primary endpoint is the composite of all‐cause mortality and intervention for HF decompensation; secondary endpoints include all‐cause mortality, intervention for HF decompensation, clinical composite score (CCS) at 6 months, atrial fibrillation, quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), health outcome measured by the EQ‐5D instrument, all‐cause readmission after a HF admission, and cost‐effectiveness. The AdaptResponse clinical trial is powered to assess clinical endpoints and is expected to provide definitive evidence on the incremental utility of AdaptivCRT‐enhanced CRT systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing

Filippatos

Birnie

Gold

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…In heart failure patients with uncontrolled HR despite medical treatment, cardiac resynchronization therapy combined with AV node ablation is recommended by current guidelines (level of recommendation, IIa) 14, 15. Since the patient was allocated to PMVR due to prohibitive risk for surgical MV repair, reduction of heart failure symptoms and prevention of recurrent cardiac decompensations were the primary treatment goal.…”

Section: Discussionmentioning

confidence: 99%

Mitral valve pressure gradient after percutaneous mitral valve repair: every beat counts

et al. 2017

View full text Add to dashboard Cite

A patient presented with symptoms of decompensated heart failure 2 months after percutaneous mitral valve (MV) repair. Echocardiography demonstrated impaired left ventricular function with elevated MV pressure gradients and pulmonary pressures during rapid atrial fibrillation. Heart rate control was achieved by implantation of a biventricular pacemaker with subsequent His‐bundle ablation because atrial fibrillation was refractory to medical treatment. During biventricular pacing at different rates (50–110 b.p.m.), heart rate correlated positively with both MV mean pressure gradient and global longitudinal strain and negatively with stroke volume. MV pressure gradients directly translated into elevated pulmonary pressures. Thus, rate control and biventricular pacing improved cardiac haemodynamics.

show abstract

“…Patients were enrolled according to the following criteria: (i) Structural heart disease complied with the indication of secondary prevention of ICD or CRT‐D9, 10, 11 and (ii) ATP therapies delivered due to monomorphic VTs during the follow‐up. Patients were excluded in line with the following criteria: (i) age<18, (ii) without structural heart disease, (iii) with ionic channel disease, (iv) ICD or CRT‐D implantation because of primary prevention, (v) without ATP therapies during the follow‐up, (vi) only with ATP therapies due to polymorphic VTs, and (vii) only with inappropriate ICD therapies due to supraventricular tachycardias.…”

Section: Methodsmentioning

confidence: 99%

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

Fang

Yang

et al. 2017

Journal of Arrhythmia

View full text Add to dashboard Cite

IntroductionVentricular tachycardia (VT) acceleration due to antitachycardia pacing (ATP) therapy could be often observed in patients with implantable cardioverter defibrillator (ICD), which usually results in additional shock. However, few studies focused on the risk factors for VT acceleration caused by ATP therapy. The purpose of this study was to investigate risk factors for VT acceleration due to ATP delivery.MethodsWe retrospectively reviewed 1056 ATP episodes in 33 patients with structural heart diseases, of whom clinical characteristics and episodes details were evaluated.ResultsAt individual patient level, number of VT morphologies recorded in electrograms during follow‐up was a risk factor with cutoff point of 1 (AUC 0.79, sensitivity 72.7%, specificity 77.3%, P < .001) to predict ATP acceleration (OR 3.50, P = .008). From episode‐based analysis, VT cycle length (VTCL) and mean variation in VTCL were risk factors to predict ATP acceleration (OR 0.98, P < 0.001 vs OR 1.06, P < .001, respectively), with cutoff points of 347 ms (AUC 0.67, sensitivity 82.5%, specificity 47.6%, P < .001) and 7.3 ms (AUC 0.66, sensitivity 77.5%, specificity 56.7%, P < .001), respectively. In addition, VTs with cycle length less than 347 ms were more likely to be accelerated by burst stimulation with more pulse numbers (OR 3.31, P < .001).ConclusionsNumber of VT morphologies, VTCL, and mean variation in VTCL are risk factors predicting ATP acceleration. Burst stimulation with less pulse numbers should be performed in VTs with cycle length less than 347 ms.

show abstract

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Cited by 2,071 publications

References 171 publications

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing

Mitral valve pressure gradient after percutaneous mitral valve repair: every beat counts

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

Contact Info

Product

Resources

About